- Report
- May 2025
- 200 Pages
Global
From €2185EUR$2,490USD£1,891GBP
- Report
- May 2025
- 188 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- May 2025
- 192 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- May 2025
- 183 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- May 2025
- 183 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- May 2025
- 198 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- February 2025
- 209 Pages
Global
From €2150EUR$2,450USD£1,860GBP
- Report
- February 2025
- 120 Pages
Global
From €5222EUR$5,950USD£4,518GBP
- Report
- July 2025
Global
From €4300EUR$4,900USD£3,721GBP
- Report
- May 2025
- 175 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- April 2025
- 175 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- April 2025
- 175 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- April 2025
- 200 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- April 2025
- 200 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- April 2025
- 200 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- March 2025
- 200 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- March 2025
- 200 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- March 2025
- 200 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- March 2025
- 175 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- March 2025
- 250 Pages
Global
From €3941EUR$4,490USD£3,409GBP

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more